Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 732

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 732
---
   |     |                     | (7,176 | ) |     |      | (11,865 | ) |
| Cash flows from investing activities                                       |     |      |   |     |                     |        |   |     |      |         |   |
| Purchase of equipment                                                      |     |      |   |     |                     |    (20 | ) |     |      |    (232 | ) |
| Net cash used in investing activities                                      |     |      |   |     |                     |    (20 | ) |     |      |    (232 | ) |
| Cash flows from financing activities                                       |     |      |   |     |                     |        |   |     |      |         |   |
| Net proceeds from the issuance of shares and warrants                      |     |      | 8 |     |                     | 10,576 |   |     |      |   1,903 |   |
| Payment of prior year issuance costs                                       |     |      |   |     |                     |      — |   |     |      |     (43 | ) |
| Series A preferred cash dividend                                           |     |      | 8 |     |                     |     (6 | ) |     |      |      (8 | ) |
| Net cash provided by financing activities                                  |     |      |   |     |                     | 10,570 |   |     |      |   1,852 |   |
| Increase (decrease) in cash and cash equivalents                           |     |      |   |     |                     |  3,374 |   |     |      | (10,245 | ) |
| Cash and cash equivalents – beginning of year                              |     |      |   |     |                     |  1,535 |   |     |      |  11,780 |   |
| Cash and cash equivalents – end of year                                    |     |      |   |     |                     |  4,909 |   |     |      |   1,535 |   |
| Supplementary information (note 11)                                        |     |      |   |     |                     |        |   |     |      |         |   |

The accompanying notes are an integral part of these consolidated financial statements. F-7

Kintara Therapeutics, Inc.

Notes to Consolidated Financial Statements

June 30, 2024

(In thousands)

1. Nature of operations, corporate history, and going concern and